Loading
Raiz Diagnostics
Raiz Diagnostics is a Boston company building a test that reads which genes are switched on in a lymphoma sample, to give a diagnosis that guides treatment at lower cost.
Also called: RAIZ DIAGNOSTICS, INC.
Overview
Raiz Diagnostics, Inc., of Boston, describes its product as an end-to-end, treatment-defining lymphoma diagnosis and offers limited beta access. In fiscal year 2026 the National Cancer Institute funded its SBIR project on a cost-effective gene expression assay for lymphoma diagnosis intended for broad implementation (5R44CA310364-02, USD 520,000).
Headquarters
Boston, MA, US
Funding
All startupsStartup
Investors not recorded; see the round sources.
Rounds on record
| Round | Year | Amount | Source |
|---|---|---|---|
| Grant · NCI SBIR (R44) award 5R44CA310364-02: Scaling Lymphoma Diagnosis: A Cost-Effective Gene Expression Assay for Broad Implementation | 2026 | $520K | reporter.nih.gov |
Amounts only where the cited source states them. Rounds without a public source are not listed.
Type
Stage
Startup
Website
Notes
- The company website was a holding page with a short description when read on 4 November 2026; the assay is described from the NIH RePORTER record.
Connected
3cancers
fronts
technologies
Sources
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
nih.gov · 1
raizdx.com · 1
A source that has moved or gone is reported by the weekly link check. /audit/